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Abstract
Glycosylation is an essential post-translational modification, which determines the function of proteins and important
processes such as inflammation. b-1,4-galactosyltransferase I (bGalT1) is a key enzyme involved in the addition of galactose
moieties to glycoproteins. Intestinal mucins are glycoproteins that protect the gut barrier against invading pathogens and
determine the composition of the intestinal microbiota. Proper glycosylation of mucus is important in this regard. By using
ubiquitously expressing bGalT1 transgenic mice, we found that this enzyme led to strong galactosylation of mucus proteins,
isolated from the gut of mice. This galactosylation was associated with a drastic change in composition of gut microbiota, as
TG mice had a significantly higher Firmicutes to Bacteroidetes ratio. TG mice were strongly protected against TNF-induced
systemic inflammation and lethality. Moreover, bGalT1 transgenic mice were protected in a model of DSS-induced colitis, at
the level of clinical score, loss of body weight, colon length and gut permeability. These studies put bGalT1 forward as an
essential protective player in exacerbated intestinal inflammation. Optimal galactosylation of N-glycans of mucus proteins,
determining the bacterial composition of the gut, is a likely mechanism of this function.
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Introduction
Glycosylation has been known to be important not only for
correct development of the intestine but also for its proper
functioning and especially for maintenance of the protective
function of the mucus layer [1]. From stomach to rectum, the
entire mucosa consists of a single layer of columnar epithelial
cells, covered by a layer of secreted mucus which is mainly
produced by specialized secretory cells known as goblet cells.
The mucus layer is a protective barrier which protects the
epithelial cells and underlying host tissues against direct contact
with commensal microbiota of the gut. Mucus is a complex
solution rich in secreted mucins [2]. These are large, heavily
glycosylated glycoproteins that assemble into homo-oligomers
that give mucus its viscous properties [3]. The apical surface of
mucosal epithelial cells is covered by a complex glycocalyx
containing large amounts of cell surface transmembrane mucins.
The extracellular heavily glycosylated part of mucins can be
shed into the mucus [4].
b-1,4-galactosyltransferase I (bGalT1) is an enzyme that plays a
major role in glycosylation. It is transcribed, in mice, by the
B4galt1 gene and it conjugates activated galactose in a b-1,4 bond
to the outer arm of N-acetylglucosamine in type 2 N-glycans [5].
B-1,4 galactosylation of glycoproteins occurs in many mammalian
tissues and is involved in various physiological functions through
interactions with selectins, galectins, asiologlycoprotein receptor
and other molecules [6].
Growth of bGalT1-knockout mice is retarded and about 50% of
the mice die before weaning, due to augmented proliferation and
abnormal differentiation of the intestinal epithelial cells [7].
Additionally, bGalT1 knockout mice display peripheral blood
leukocytosis and reduced acute and chronic inflammatory
responses [8], which shows that bGalT1 plays an important role
in inflammation. Links between tumor necrosis factor (TNF), a
very potent proinflammatory molecule and a key signaling
component of the immune system [9] and bGalT1 expression
are known. First, stimulation of several cell types with TNF in vitro
increases bGalT1 expression [10–12]. Second, in vivo, spinal cord
contusion injury as well as injection of LPS into the spinal cord
induce bGalT1 expression, and it was suggesting that TNF might
play a role in regulating bGalT1 expression. However, direct
induction of bGalT1 gene expression by TNF in vivo has not been
demonstrated [13,14].
Inflammatory bowel disease (IBD) is a TNF-dependent,
immune-mediated disease resulting from a disturbed interaction
between gut microbiota and mucosal cells in genetically suscep-
tible hosts [15,16]. The role of TNF in IBD is well established and
TNF is a successful drug target in IBD. Also, TNF is a mediator in
sepsis and we recently proved that the gut is an essential target in
TNF’s induction of systemic inflammatory response syndrome
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(SIRS), in a sepsis-like mouse model [17]. Deterioration of the
mucus layer of the colon is commonly observed in patients with
ulcerative colitis, a common form of IBD [18,19]. The importance
of mucus in protecting against IBD is supported by different mouse
models, e.g. Winnie mice, which have a missense mutation in the
Muc2 mucin gene, and Muc22/2 mice, which develop spontane-
ous colitis [20,21]. Besides N-glycans, also O-glycans in mucus are
known to be essential for protection against colitis. Mice lacking
core-3- and core-2-derived O-glycans are more susceptible to
colitis [22,23]. Mice deficient in core-1-derived O-glycans even
spontaneously develop colitis [1]. But hardly any studies have been
performed on the relevance and importance of N-glycosylation,
and particularly galactosylation, during colitis [24].
To investigate the role of bGalT1 in TNF-mediated diseases
such as sepsis and IBD, we generated mice overexpressing bGalT1
(TG) and subjected them to TNF-induced SIRS and DSS-induced
colitis. We demonstrate that bGalT1 TG mice are resistant to
TNF-induced lethal SIRS and that bGalT1 expression in the gut
of WT mice increases after TNF injection. Likewise, TG mice are
more resistant to DSS-induced colitis. We hypothesize that the
main mechanism for these effects is the protective effect of fully
galactosylated mucus in the intestine of the TG mice, which leads
to a healthier Firmicutes/Bacteroidetes ratio.
Results
Generation and phenotyping of mice overexpressing
bGalT1 (TG)
Using the Gateway-compatible ROSA26 locus targeting vector
[25], we generated conditional bGalT1-overexpressing mice by
knocking in the mouse bGalT1 cDNA preceded by a loxP-flanked
stop cassette under control of the ROSA26 promoter (Fig. 1A).
Correctly targeted embryonic stem cell clones were identified by
Southern blotting and were used to generate chimeric mice that
transmitted the transgene to their offspring (Fig. 1B). Mice
homozygous for the loxP-flanked stop cassette were used as
control mice (CT). They did not display altered bGalT1
expression compared to WT mice (data not shown). CT mice
were crossed with deleter-cre mice expressing Cre in all cell types
[26]. Mice heterozygous for the transgene and containing one Cre
copy were intercrossed to obtain the homozygous transgenic mice
(TG) which were used in all experiments. Efficiency of excision of
the stop cassette by Cre was confirmed by performing PCR on tail
genomic DNA for Cre and for the stop cassette (Fig. 1C).
The TG mice were born without obvious defects and were
found to have 2 fold higher expression and activity levels of
bGalT1 in all the organs tested (Fig. S1).
Next, we focused on the gut because proliferation of the
intestinal epithelial cells in bGalT12/2 mice is augmented and
their differentiation is abnormal [7]. Mucosa of the small intestine
and colon were isolated from CT and TG mice and mRNA was
prepared. TG mice expressed a two-fold higher level of bGalT1
mRNA than CT mice in the mucosa of ileum and colon (Fig. 2A).
bGalT1 activity assays demonstrate a similar trend as the bGalT1
gene expression namely a two-fold higher bGalT1 activity is
present in the ileum and colon of TG compared to CT mice
(Fig. 2A). As judged by H & E staining, this increased expression
and activity did not alter the mucosa morphology in ileum and
colon (Fig. 2B–C) nor the proliferation rate in the mucosa of ileum,
as assessed by Ki67 staining (Fig. 2D).
It has been reported that bGalT12/2 mice display basal
peripheral blood leukocytosis [8], so blood composition was
analyzed, but no differences between TG and CT mice could be
detected (Fig. S2). These data show that the TG mice display no
obvious abnormalities in the composition of the mucosa of the gut.
Proper functioning of intestinal mucus depends on its glycosyl-
ation. It has been reported that N-glycosylation of mucins is
important for folding, oligomerization and surface localization of
these proteins [27]. Recent studies showed that O-glycosylation of
mucus is essential for its functionality, but little is known about
functional importance of N-glycosylation of mucins [1,22]. To
address this, we visualized the goblet cells, the major mucus-
producing cells of the intestine, by Alcian blue staining in the small
intestines of CT and TG mice. However, no difference in amount,
size or localization of goblet cells could be observed (Fig. S3A). We
also measured the total amount of mucus present in ileum of CT
and TG mice. Also here, no difference in amount of mucus per cm
ileum could be detected (Fig. S3B). Next, we performed a
qualitative analysis of the mucus. We isolated the mucus from the
ileum, isolated all N-glycans, and separated them according to size
by the DSA-FACE, a technique widely validated and used to study
N-glycosylation [28–33]. A clear difference in ileum mucus N-
glycosylation profile was observed between CT and TG mice
(Fig. 2E). The mucus of CT mice displayed a very high peak,
running with the same mobility as M7 of the reference RNaseB,
which is the mobility position of non-galactosylated structures in
human serum, while in the mucus of TG mice, this peak was
absent. To confirm that this peak represents N-glycans that are not
terminally galactosylated and possibly are GlcNAc-terminating
acceptors, we performed a glycodigest with hexosaminidase, an
enzyme that cleaves GlcNAc only if it is attached terminally. This
enzymatic cleavage reduced the peak running around M7, which
confirms that this peak contains a structure that does not end with
galactose but with GlcNAc (Fig. 2E). Also other peaks present in
CT mucus have a terminal GlcNAc since more peaks (not only the
one running at same mobility as M7) shift after hexosaminidase
treatment. In contrast, hexosaminidase digestion of TG N-glycans
does also alter the profile, but to a far lesser extent demonstrating
that a 2 fold bGalT overexpression increases the galactose
terminating structures in mucus but is not sufficient to cover all
terminal GlcNAcs (Fig. 2E). To confirm that more N-glycans of
TG mice are terminally galactosylated compared to CT mice, b-
galactosidase digests were performed on the same sugars. b-
galactosidase is an enzyme that cleaves galactose only if it is
attached terminally. Treating CT sugars with b-galactosidase
modified the CT profile to some extent but severely less than the
TG sugars treated with b-galactosidase, where a total shift of peaks
occurred (Fig. 2F). This demonstrates again that a 2 fold
overexpression of bGalT increases the galactose terminating
structures in the mucus of ileum from the TG mice. We observed
a similar increase in galactose terminating N-glycans in colon
mucus of TG mice compared to CT mice (Fig. S3C–D).
bGalT1 modulates the gut microbiota composition
Glycans on mucins are necessary for interaction between mucus
and microbial lectins. Hence, altered mucin glycosylation can
modify microbiota composition [34]. The gut microbiota is a
crucial protective component of the gut mucosa, and it is also
thought to contribute to gut tissue repair [35].
As we demonstrated that the N-glycan profile is significantly
altered in mucus of TG mice, we compared the microbiota
composition of TG mice and CT mice. Bacterial DNA was
isolated from mouse feces and qPCR was performed with primers
specific for the main bacterial species groups found in the gut, and
the results were normalized to total amounts of bacteria. The total
amount of bacteria was similar in CT versus TG mice (data not
shown). We did found fewer Bacteroidetes and more Firmicutes in
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TG mice than in CT mice (Fig. 3A–B). TG mice had a
significantly higher Firmicutes to Bacteroidetes ratio (Fig. 3C).
We demonstrate that increased bGalT1 expression can signifi-
cantly alter this ratio to a more protective microbial constitution,
since reduced counts of Firmicutes are known to be consistently
associated with reduced protection of the gut mucosa, as seen in
IBD patients, infants and elderly individuals [35,36].
Furthermore, we analyzed if this altered Firmicutes to
Bacteroidetes ratio had an impact on Paneth cell composition.
Paneth cells in mouse small intestinal crypts secrete granules rich
in microbicidal peptides when exposed to bacteria or bacterial
antigens [37]. We visualized the Paneth cells by PAS and MMP-7
staining [38,39]. The amount of Paneth cells are similar in CT and
TG ilea (Fig. 3D). TG Paneth cells do have reduced granule
content compared to CT Paneth cells (Fig. 3E) suggesting there is a
reduced need of anti-bacterial peptide production in the TG mice
due to a ‘‘healthier microbiota’’ composition.
Next, we analyzed whether this altered microbiota composition
is protective in inflammation models by subjecting CT and TG
mice to TNF-induced SIRS, a model in which the gut is a crucial
target [17] and DSS-induced colitis.
bGalT1-overexpressing mice are resistant to TNF-induced
inflammatory shock
TNF causes severe damage to the intestine [40], and the
intestine is an important regulator of TNF-induced shock
[17,41,42]. Also, depleting bacteria by antibiotic treatment
reduces the severity of TNF-induced inflammation and intesti-
nal damage [43]. We investigated whether increased mucus
galactosylation and consequent increased Firmicutes/Bacteroi-
detes ratio’s alters TNF toxicity. We injected CT and TG mice
with TNF and monitored survival (Fig. 4A) and body
temperature (Fig. 4B). Inflammation was monitored by serum
IL-6 levels (Fig. 4C) [44].
Figure 1. Generation of TG mice overexpressing bGalT1. (A) ES-cell targeting strategy, adapted from [25]. Restriction enzyme sites and the
location of the probe used for Southern blot analysis are depicted. The ROSA26 locus was targeted using the targeting vector (top) by homologous
recombination. After antibiotics selection and Southern blot analysis, the ROSA26 locus was modified as shown in the figure. (B) Southern blot
analysis on DNA derived from WT and heterozygous recombinant ES cells after BamH1 digestion and using the probe depicted in panel A. (C) PCR
analysis on tail-extracted genomic DNA of two TG mice (with floxed bGalT1 alleles and containing cre) and two CT mice (mice with floxed bGalT
alleles but not containing cre). PCR on genomic DNA was performed to detect the floxed Neomycin resistance gene (upper panel) and the cre gene
(lower panel).
doi:10.1371/journal.pone.0079883.g001
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In terms of survival, a significant protection against TNF was
found in the TG mice: most TG mice survived the challenge, while
half of the CT mice died (Fig. 4A). This different response was also
reflected in body temperature. While both groups displayed an
initial drop in body temperature, TG mice recovered much faster
than CT mice. Furthermore, IL-6 serum levels after TNF injection
were significantly lower in TG mice than in CT mice. This
demonstrates that TG mice experience less severe systemic
inflammation and cope better with TNF-induced inflammatory
shock. Because bGalT12/2 mice were shown to suffer from
Figure 2. Basic characteristics of TG mice overexpressing bGalT1. (A) Relative bGalT1 gene expression and bGalT1 activity in the ileum and
colon mucosa of bGalT1-overexpressing mice (TG) mice (black, n = 5) is 2 fold higher compared to CT mice (red, n = 6). Top left bGalT1 QPCR in ileum
mucosa and top right bGalT1 QPCR in colon mucosa. Below left bGalT1 activity in ileum and below right bGalT1 activity in colon. Representative H&E-
stained (B) ileum and (C) colon mucosa from CT (left) and TG (right) mice. The bar in the left corner represents 50 mm. No morphologic alterations are
observed in the TG mice. (D) Ki67-stained ileum mucosa from CT (left) and TG (right) mice. The bar in the left corner represents 50 mm. No changes in
proliferation rate are observed in the TG mice. (E) Analysis of the N-glycosylation profile of ileum mucus from mice with and without hexosaminidase
treatment. Top panel is the N-glycosylation profile of a standard protein, RNase B. The second panel represents a representative sample of ileum
mucus of a CT mouse with a high peak running at the same position as M7 of RNaseB. The third panel represents the N-glycosylation profile of CT
mucus (the same sample as shown in panel 2), but after hexosaminidase treatment, which demonstrates that the peak running at M7 position
contains terminal GlcNAc. The fourth panel is a representative sample of ileum mucus of a TG mouse, lacking the M7 peak. The fifth panel is the same
sample as in the fourth panel but after hexosaminidase treatment, demonstrating that TG mucus has less structures ending with GlcNac compared to
CT mucus. (F) Analysis of the N-glycosylation profile of ileum mucus from mice with and without ß-galactosidase treatment. Top panel is the N-
glycosylation profile of RNase B. The second panel represents a typical sample of ileum mucus of a CT mouse. The third panel is the same sample as
the second panel but treated with ß-galactosidase. After isolation of the N-glycans out of mucus, these N-glycans are treated with ß-galactosidase in
order to identify terminal galoctose residues in the sample since ß-galactosidase only cleaves terminal galactose. Only a few peaks shift, which
demonstrates that only a small amount of the N-glycans in CT mucus have terminal galactose. The fourth panel is a representative sample of ileum
mucus of a TG mouse. The fifth panel is the same sample as in the fourth panel but treated with ß-galactosidase. Here a clear shift of peaks is
observed demonstrating that the N-glycans in TG mucus have more terminal galactose compared to the CT mucus.
doi:10.1371/journal.pone.0079883.g002
bGalT1 Protects the Gut against Inflammation
PLOS ONE | www.plosone.org 4 December 2013 | Volume 8 | Issue 12 | e79883
bGalT1 Protects the Gut against Inflammation
PLOS ONE | www.plosone.org 5 December 2013 | Volume 8 | Issue 12 | e79883
peripheral blood leukocytosis and reduced inflammatory responses
caused by impaired rolling of white blood cells [8], we analyzed
the peripheral white blood cell composition in CT and TG mice
after TNF injection, but no differences were found (data not
shown). Similarly, we detected the same amount of CD45 positive
white blood cells per surface area in the ileum of CT and TG after
TNF challenge (for representative examples see Fig. 4D). Our
results suggest that overexpression of bGalT1 reduces TNF-
induced inflammation at the level of the intestines but does not
directly influence the infiltration capacity of leukocytes.
TNF induces bGalT1 expression in vivo in the mucosa of
the gut
TNF-induced bGalT1 expression has been demonstrated in vitro
in astrocytes, Schwann cells and fibroblast-like synoviocytes [10–
12]. To study the effect of TNF on bGalT1 expression in vivo, we
injected CT mice with TNF, isolated ileum mucosa and examined
bGalT1 gene expression by qPCR. We focused on the ileum
mucosa because the small intestine is a main target of TNF in the
process of TNF-induced shock [40,43,45,46]. We found that
bGalT1 expression is induced in the mucosa as early as 4 h after
TNF injection and that its expression is even higher 8 h post-
injection (Fig. 4E). Although this increase is limited it is clearly
significant indicating that TNF is an inducer of bGalT1 gene
expression in vivo.
bGalT1 TG mice display reduced susceptibility to DSS-
induced colitis
The fecal microbiota composition of patients with IBD differs
from that of healthy individuals. qPCR and sequencing analysis
shows that Firmicutes bacteria in particular are underrepresented
in IBD patients [35]. Firmicutes bacteria have anti-inflammatory
properties: oral administration of live Firmicutes bacteria reduced
the severity of TNBS colitis in mice [47]. Therefore, a high ratio of
Firmicutes to Bacteroidetes is thought to be protective against
colitis.
As we detected a higher ratio of Firmicutes to Bacteroidetes in
gut microbiota of TG mice and these mice were found to be
significantly less susceptible to TNF, the toxicity of which clearly
involves the gut [17], we compared CT and TG mice in a TNF-
mediated gut inflammatory model, i.e.colitis induced by dextran
sulfate sodium (DSS) [15]. Many morphological and pathophys-
iological features of DSS-induced colitis are similar to those
observed in human ulcerative colitis, such as the production of
inflammatory cytokines and loss of barrier function [48,49]. Mice
received 3% DSS in the drinking water for 5 days, and body
weight, diarrhea and rectal bleeding were monitored daily,
yielding a clinical score. Compared to CT mice, TG mice
developed less severe symptoms of colitis, such as milder gross
rectal bleeding and diarrhea, leading to a lower clinical score
(Fig. 5A). Also, the TG mice were protected against loss of body
weight (Fig. 5B). In agreement with the clinical observations, there
were clear morphological differences in the colons of CT versus
TG mice after 4 days of DSS treatment. The CT colons
demonstrate a severe loss of crypt architecture and overall
structure of the lamina propria and a significant decrease in
goblet cell amounts (Fig. 5C); this was not seen in the colons of TG
mice 4 days after DSS treatment (Fig. 5D).
Additionally, colon shortening, a typical clinical feature of colon
inflammation and of the DSS model, was significantly more
pronounced in CT mice than in TG mice, after 4 days of DSS
treatment (Fig. 5E). Colon permeability has been shown to be a
critical step in susceptibility to colitis [50]. Therefore, we measured
gut leakage in CT and TG mice after 4 days of DSS treatment.
FITC-dextran was administered orally to both groups of mice and
five hours after gavage, blood was taken and fluorescence was
measured in the plasma, as described before [51]. We observed no
differences in basal gut permeability, but a significantly reduced
increase in gut permeability in the TG mice compared to the CT
mice (Fig. 5F). Taken together, these results demonstrate that
bGalT1 TG mice are strongly protected against DSS-induced gut
barrier disruption and other DSS-induced phenomena. In
conclusion, bGalT1 overexpression protects against TNF-mediat-
ed inflammatory colitis.
Discussion
Oligosaccharides of glycoproteins play important biological
roles by influencing the functions of the proteins to which they are
attached [52]. They are important for maintaining the complex
life of cells in multicellular organisms by modulating cell adhesion,
self/nonself recognition, molecular trafficking and many other
functions [53,54].
bGalT1, is very important in the glycosylation process since, in
the Golgi apparatus, it transfers galactose from uridine diphos-
phate galactose to terminal GlcNAc of carbohydrate chains in a b-
1,4-linkage to form a Galb1-4GlcNAc structure [55]. bGalT1 is
expressed ubiquitously, suggesting that it is involved in b4
galactosylation of many glycoproteins. b4 galactosylation of
glycoproteins is widely distributed in mammalian tissues and is
involved in various physiological functions [14,56,57].
To find the true biological function of bGalT1 in mammals,
mutant mice can be generated. bGalT1-deficient mice have been
described. We here describe, for the first time, bGalT1 overex-
pressing mice. In bGalT1-deficient mice, inflammatory responses
are suppressed and neutrophil infiltration at inflammatory sites is
reduced [8] but also skin wound healing is significantly delayed
[58]. Although bGalT12/2 mice are useful for studying the
function of bGalT1, they also demonstrate developmental defects,
such as growth retardation, and the proliferation and abnormal
differentiation of the intestinal epithelial cells [7]. To circumvent
these developmental abnormalities and to generate a novel and
interesting complementary tool, we generated bGalT1-overex-
pressing mice and studied their response in inflammatory models
involving the gut. The mice were born normally without obvious
defects, and their blood leukocyte compositions and counts were
normal. In contrast to bGalT12/2 mice, our TG mice showed no
abnormal differentiation or proliferation of the mucosa but a
difference in the N-glycosylation composition of the mucus was
observed. While CT mucus contains glycoproteins with N-glycans
terminating with GlcNAc (so without terminal galactose), TG
Figure 3. Microbiota composition in CT and bGalT1 mice. Fecal bacterial DNA was isolated from CT mice (black, n = 12) and TG mice (red,
n = 12) and qPCR was performed with primers specific for the main bacterial species normally found in the gut. After the qPCR, the results were
normalized to the total amount of bacteria. (A) Bacteroidetes are reduced and (B) Firmicutes are increased in the TG mice compared to CT mice. (C)
The Firmicutes to Bacteroidetes ratio is significantly increased in TG mice compared to CT mice. (D) Visualization of the Paneth cell numbers in ileum
by PAS staining. Representative CT sample on the left and TG sample on the right. TG mice have similar amounts of Paneth cells compared to CT
mice. (E) Visualization of the Paneth cells granules by MMP-7 staining in ileum. Representative CT sample on the left and TG sample on the right. TG
Paneth cells have reduces granule content compared to CT Paneth cells.
doi:10.1371/journal.pone.0079883.g003
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mucus glycoproteins are almost fully galactosylated. This demon-
strates that under normal physiological conditions bGalT1 cannot
perform galactosylation of all mucus N-glycoproteins. By overex-
pressing bGalT1 some 2–3 fold, almost all N-glycoproteins in the
mucus become N-galactosylated.
Mucus is a complex, gel-like fluid that forms a continuous
protective layer over the surface of the gastrointestinal mucosa
from stomach to rectum. It protects the delicate underlying
intestinal epithelial cells (IEC) against pathogens from the lumen
[59]. Mucus is rich in mucin glycoproteins that are heavily N- and
O- glycosylated [2]. On the other hand, the mucus layer provides
an energy source for the endogenous microbiota that colonize it,
and thereby the mucus sustains the health status of the gut
microbiota, [60] which is important since the gut microbiota
contribute to host nutrition and energy balance and to the
development and maintenance of a robust immune system [61].
Different bacterial species groups bind to different N-glycan
epitopes [62,63]. Therefore, a change in glycosylation of the
mucosa can influence the binding of bacteria to it. For example,
mice lacking the enzyme fucosyltransferase-2 display altered
glycosylation of mucins leading to altered binding of Helicobacter
pylori to the gastric mucosa [64]. We therefore studied the effect of
increased mucus galactosylation in TG mice on the gross
microbiota composition. In TG mice, Firmicutes were increased
and Bacteroidetes were decreased, which resulted in a very
significantly higher Firmicutes/Bacteroidetes ratio. Such high
ratios have been postulated to be protective against IBD [35].
Thus changes in the expression of a single glycosyltransferase can
have a large effect on the crucial composition of the gut
microbiota. Inversely, it has been demonstrated that bacteria
can induce alterations in the expression of host glycosyltransferases
and glycosidases in the gut [65]. Further study is required to
determine whether Firmicutes can induce the expression of
bGalT1 or if other commensal bacteria can specifically regulate
the galactosylation state of the mucus. Such studies can shed light
on how the composition of microbiota is determined and how it
can be regulated and manipulated.
The TG mice have less anti-microbial products in their Paneth
cells. This could be caused by a reduced need of anti-bacterial
protein production in the TG mice due to a ‘‘healthier
microbiota’’ composition. Few studies discuss how microbiota
composition influences Paneth cell anti-bacterial peptide produc-
tion [66]. How microbial composition influences Paneth cell
granule composition in the intestine should be studied further in
depth.
To study if this altered N-glycosylation profiles and the
microbiota compositions of the gut are protective against TNF-
mediated inflammatory responses, we tested TG mice in
inflammatory models in which the gut and the microbiota play a
crucial role [15,17,42]. Commensal bacteria are crucial for TNF-
induced toxicity. Depletion of bacteria by antibiotics reduces the
severity of TNF-induced gut inflammation and damage [17,43].
Our TG mice survived an otherwise lethal injection of TNF and
developed milder inflammation than CT mice.
Additionally, expression of bGalT1 was increased in the mucosa
of CT mice in response to TNF, confirming previous in vitro data
that TNF induces bGalT1 [10,11]. Elevated bGalT1 expression
might play a role in increased rolling of leukocytes. However,
bGalT1-overexpressing mice showed no alterations in rolling of
leukocytes. This observation challenges the notion that the role of
bGalT1 in inflammation is limited to its effect on the rolling of
leukocytes [7,8]. Apparently, bGalT1 overexpression provides
protection through other mechanisms. Modified N-glycosylation
caused by TNF-induced bGalT1 expression might provide
protection by changing the niche occupied by the bacteria and
thereby reducing the chances of systemic bacterial infiltration and
the risk of systemic inflammation but more studies are needed to
unravel the mechanism in detail. It was recently reported that
cytokines such as IL-6 and IL-8 mediate changes in mucin
glycosylation. This could be a mechanism that modifies the pattern
of glycosylation to increase the anti-inflammatory status of the
mucus layer during infection [67,68].
Mucosal O-glycans are known to be protective in colitis. Mice
lacking core-3- and core-2-derived O-glycans are more susceptible
to colitis [22,23]. Mice deficient in core-1-derived O-glycans even
develop colitis spontaneously [1]. The N-glycosylation status of the
gut has not been studied extensively in the context of colitis. Only
recently, it has been shown that the induction of colitis by DSS is
slightly reduced in bGalT1 heterozygous mice [24]. However, it
must be noted that bGalT1 knockout mice have serious
developmental problems and half of them die before weaning.
In the surviving mice, proliferation of IEC is augmented and their
differentiation is abnormal. Also, these mice have an increased
epidermal thickness, which also could be the case in the bGalT1+/2
mice [7], and which could explain their partial protection against
DSS.
In our studies we show that bGalT1 TG mice are resistant to
DSS-induced colitis, which points to the importance of exploring
disregulation of bGalT1 expression in colitis patients. Additionally,
bGalT1 gene or promoter SNP analysis could reveal if genetic
alterations in the major N-galactosylation machinery can be
involved in the pathogenesis of colitis. Our data also suggest that
therapeutic strategies that enhance the galactosylation state of the
gut (such as the use of probiotics or small molecules) could have
beneficial effects on disease outcome.
It has been shown that the size of the non-galactosylated N-
glycan fraction in human IgG is significantly higher in patients
with Crohn’s disease. Moreover, bGalT1 expression and activity
in B cells are lower in patients with Crohn’s disease [69]. We
initially hypothesized that higher bGalT1 levels would reduce the
amount of non-galactosylated IgGs and thereby protect the TG
mice against DSS-induced colitis. However, during the short
period of DSS-induced colitis (5 days) no non-galactosylated IgGs
were found in CT or TG mice, demonstrating that in our model
the galactosylation status of the IgGs cannot be responsible for the
observed protection. As a high Firmicutes to Bacteroidetes ratio is
believed to be protective in colitis [35], we hypothesize that the
protective mechanism resides in the more protective constitution
of the microbiota in the gut and further studies (including mice
with BGalT overexpression only in the mucosa) are needed to
unravel the mechanism in detail.
Figure 4. Mice overexpressing bGalT1 are protected against TNF-induced inflammatory shock. TNF (20 mg/mouse) was injected in CT
(black line, n = 9) and TG (red line, n = 13) mice. Survival (A) and body temperature (B) were followed during the experiment over a period of 50 h. No
further deaths occurred. (C) IL-6 serum levels were measured in CT mice (black bars, n = 5) and TG mice (red bars, n = 7), 4 hours and 8 hours after TNF
injection. Staining of CD45 positive white blood cells in the ileum of CT (D left) and TG mice (D right) 4 hours after TNF challenge, by
immunohistochemistry. A representative CT and TG sample are shown. The bar in the left corner represents 50 mm. No significant difference in the
number of CD45 positive cells per surface area was observed. (E) Relative bGalT1 gene expression, measured by qPCR in mucosal samples from CT
mice after injection with recombinant mouse TNF (20 mg/mouse), is upregulated in function of time.
doi:10.1371/journal.pone.0079883.g004
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In summary, bGalT1-overexpressing mice are resistant to TNF-
induced SIRS and DSS-induced colitis. We hypothesize that the
underlying mechanism is an increase in the galactosylation status
of the gut protecting mucus, leading to a healthier Firmicutes/
Bacteroidetes ratio in the gut, which protects against inflammatory
and chemical insults such as TNF and DSS at the levels of the gut.
Materials and Methods
Generation of bGalT1 overexpression mouse
The gateway compatible ROSA26 locus targeting vector for
conditionally overexpression of b4GalT1 was generated as
previously described (Nyabi et al., 2009). G4 ES cells [70] were
grown and manipulated at 37uC in 5% CO2 on mitomycin C-
treated mouse embryonic fibroblasts, derived from TgN (DR4)1
Jae embryos, in high glucose DMEM (Invitrogen), supplemented
with 15% ES cell-grade FBS (HyClone), 0.1 mM 2-mercaptophe-
nol, 2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM non-
essential amino acids and 1000 U/ml recombinant LIF (DMBR/
VIB Protein Service facility). Parental ES cells were electroporated
with the ROSA26 locus targeting vector. G418 resistant ES-cell
clones were screened by PCR using both an external (59
TAGGTAGGGGATCGGGACTCT 39) and an internal (59
GGGCATCGACTTCAAGGAGGACGG 39) primer to generate
a 1.5-kb fragment. PCR-positive clones were confirmed by
Southern blotting for correct 59 and 39 integration and single-
copy insertion as described previously (Nyabi et al., 2009).
Chimaeras were generated by aggregation of correctly ROSA26-
targeted ES cells with Swiss eight-cell stage embryos. Chimeras
were crossed with C57BL/6J mice to test for germline transmis-
sion.
Southern blot analysis ES cells
Genomic DNA (10 ug) was digested overnight with 50 Units
BamHI in a volume of 45 ml. Samples were loaded on a 0,8%
buffer in TAE electrophoresis buffer (0,04 M Tris-acetate, 0,002
M EDTA, pH 8,5) and run at 35 V overnight. The gels were then
soaked for 15 min in 0,25 M HCl (depurination buffer). After
rinsing with deionised water the gels were denatured for 40 min in
1,5 M NaCl, 0,5 M NaOH, neutralized for 30 min in 1,5 M NaCl,
0,5 M Tris pH 7,2, 0,001 M EDTA pH 8, washed with 26SSC
and blotted overnight with 106SSC on Hybond N+ membranes
(GE Healthcare). The membranes were then washed with 26
SSC, UV cross linked and stored at 220uC. For hybridisation, the
membranes were preincubated in Rapid-hyb hybridisation buffer
(GE Healthcare) for 1 h at 65uC under rotation. A 59 external
restriction fragment of 550 bp used as hybridisation probe was
denatured and labeled with 32P marked dCTP (Perkin Elmer)
using the Rediprime II Random Prime Labelling System (GE
Healthcare). Labeled probe was purified on MicroSpin S-300 HR
colmuns (GE Healthcare), heat denatured, added to the hybrid-
isation buffer and membranes were rotated overnight at 65uC.
Membranes were washed with prewarmed washing buffer
0,46SSC/1%SDS for 15 min and with 0,26SSC/1%SDS for
an additional 15 min at 65uC under shaking. Next, the blots were
exposed to a Phosphorimager screen for 3 days. The Phoshor
screen was scanned using a Phosphor Imager of Bio-Rad. 59
integration was confirmed as a 5.8 kb wt allele and 3.0 kb targeted
allele.
PCR for stopcassette and Cre
PCR reaction was performed with Taq Polymerase Kit of
Invitrogen (final concentration 1,875 mM MgCl2, 0,5 mM for and
rev primer, 0,25 mM XTPs and 0,5 Units Taq polymerase). PCR
cycling for stopcassette consisted of denaturation at 94uC for
5 min, 35 cycles of 94uC for 1 min, annealing at 57uC for 1 min
and extension at 72uC for 2 min, followed by 10 min at 72uC.
PCR cycling for Cre consisted of denaturation at 94uC for 2 min,
29 cycles of 94uC for 30 sec, annealing at 58uC for 30 sec and
extension at 72uC for 30 sec, followed by 2 min at 72uC. Primer
sequences were used as follows: PCR stopcassette: forward primer
GTGATCTGCAACTCCAGTCTTTC; reverse primer CCAT-
CTGCACGAGACTAGTG; PCR Cre: forward primer CGG-
TCGATGCAACGAGTGATGAGG; reverse primer CCAGA-
GACGGAAATCCATCGCTCG.
UDP-Galactosyltransferase Assay in liver
The activity of bGalT1 in the liver was measured in CT versus
TG mice. The UDP-galactosyltransferase Assay was performed
with the kit of SIGMA (Missouri, USA). The assay is based on the
transfer of radioactively labeled galactose from UDP-[galactose-
14C] to N-acetyl-D-glucosamine by UDP-galactosyltransferase.
The test reaction (with acceptor) consisted of 5 ml of assay buffer,
5 ml of manganese chloride Solution, 5 ml of UDP-Gal Solution
(10 mM), 5 ml Acceptor solution, 5 ml radiolabeled UDP-Gal
(0,5 uCi) (Perkin Elmer) and 25 ml of protein sample (50 mg)
(freshly prepared). A background control (without acceptor) was
performed in parallel.
The reactions were incubated at 37uC for 1 hour.
The reaction product, a radiolabeled N-acetyl-D-lactosamine is
then purified by ion-exchange chromatography. The eluate is
quantified by liquid scintillation counting with a Packard
instrument (together with the determination of the total cpm of
the radioactive substrate UDP-Gal in a single assay). The bGalT1
activity was 2.5 times increased in the liver of TG compared to CT
mice.
UDP-Galactosyltransferase Assay in ileum and colon
Proteins from the ileum and colon samples of CT and TG mice
were isolated with the ProteoExtract Native Membrane Protein
Extraction Kit (Calbiochem). Protein concentration was measured
with the BCA Protein Assay Kit (Pierce). To measure the
galactosyltransferase activity of the protein samples, we used the
Glycosyltransferase Activity Kit of R&D (UK).This kit takes
advantage of a specific phosphatase to remove inorganic
phosphate quantitatively form the leaving nucleotide diphoshate
such as GDP, of glycosyltransferase reactions. The released
inorganic phosphate is then detected by Malachite Green
phosphate detecting reagents. The amount of inorganic phosphate
released by the coupling phosphatase is equal to the nucleotide
sugar consumed or glycoconjugate product generated; therefore,
Figure 5. Mice overexpressing bGalT1 are protected against DSS-induced colitis. (A) Clinical score and (B) body weight of CT (black, n = 20)
and TG (red, n = 20) mice treated with 3% DSS in the drinking water. H&E staining of the colon of (C) CT mice and (D) TG mice after 4 days of DSS
treatment. Two representative CT and TG sample are shown. The bar in the left corner represents 50 mm. (E) Colon length of CT mice (black, n = 15)
and TG (red, n = 15) mice after 4 days of 3% DSS treatment. (F) Determination of DSS-induced gut permeability in CT (black, n = 17) and TG (red,
n = 14) mice. FITC-dextran was administered orally to both groups of mice, 4 days after the start of DSS treatment. Five hours after gavage, blood was
taken and fluorescence in plasma was measured. Two control CT and TG mice, not treated with DSS, but only with FITC-dextran were included.
Fluorescence in plasma increased due to leakage of FITC-dextran from the intestine into the blood significantly more in CT than TG mice.
doi:10.1371/journal.pone.0079883.g005
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the rate of inorganic phosphate production reflects the kinetics of
the glycosyltransferase reaction.
The reaction consisted of 10 ul UDP-Galactose donor (Calbio-
chem) (0,5 mM), 10 ul N-Acetyl-D-glucosamine acceptor (Sigma)
(5 mM) and 5 ul Coupling Phosphatase 1 (20 ng/ul) in a total
volume of 25 ul per well, with addition of 25 ul of the protein
sample (4 ug). All samples were assayed in duplicate.
A 2-fold serial dilution was made of a positive control,
Recombinant Human b-1,4-Galactosyltransferase (R&D systems)
and reactions were initiated with the same donor-acceptor-CP
mix. For a negative control, 16Assay Buffer was used in place of
the galactosyltransferase. A 2-fold serial dilution was made of the
phosphate standard to generate a standard curve. The reactions
were incubated at 37uC for 20 min. Malachite Green reagents
were added and the plate was incubated for 20 min at room
temperature to stabilize the color development. The optical
density of each well was determined using a microplate reader set
at 620 nm and the OD was adjusted by subtracting the reading of
the negative control.
The corrected ODs of of the positive control samples were
plotted against the amounts of galactosyltransferase. The specific
activity of the enzyme was calculated using the following equation
Specific Acitivity~
S OD=ugð Þ|CF pmol=ODð Þ
Time 20 minutesð Þ
S=Slope of the line
CF=Conversion factor = slope of the linear regression line of
the phosphate standard curve
The activity (pmol/min) of galactosyltransferase in the samples
was calculated using the regression line of the positive control and
this equation.
The bGalT1 activity was 1,5 to 2 times increased in the ileum
and colon of TG compared to CT mice.
Mice
All CT and TG mice were kept in an air-conditioned,
temperature-controlled, specific pathogen free animal house under
a 12-h light cycle. All mice were born and raised in the same room
and had free access to food and water. All experiments were
approved by the ethical committee of the Faculty of Sciences of
Ghent University.
Isolation of mucus from the intestine
CT and TG mice were anesthetized and the small intestines and
colons were dissected out. The intestines were flushed with ice-cold
PBS. Next, the ilea or colons were closed with thread at one end
and 1 ml of 10 g/L docusate sodium salt solution was instilled into
it. The other end of the intestine was then closed with thread,
creating a ‘‘sausage’’. The intestines were incubated in PBS
overnight at RT. The next day, one end of the intestine was cut
and the mucus was collected.
Mucus quantification
Five cm ileal segment was collected, weighted and used for
mucus quantification. The ileal section was opened, everted and
soaked for 2 h in a 0.1% solution of Alcian blue dissolved in
0.16M sucrose and buffered with 0.05M sodium actetate at a pH
of 5.8. Sections were washed in a 0.25 M sucrose solution for
15 minutes and washed in a fresh 0.25 M sucrose solution for
45 minutes to extract uncomplexed dye. Sections were placed in a
10 g/L docusate sodium salt solution overnight at room temper-
ature to extract absorbed dye from the tissue and then centrifuged
at 7006g. 100 ul of each sample (in triplicate) was plated on a 96-
well plate and the density was measured at 620 nm to determine
the amount of absorbed dye in each sample. The results are
reported as micrograms of alcian blue/gram of ileum.
N-glycosylation profiling of mucus
The mucus protein concentration was measured and 120 mg
was used for isolation of N-glycans, which were separated
according to size by DSA-FACE as described previously [32].
To verify the peaks contain structures with terminal GlcNAc
rather than galactose, we performed glycodigests with Streptococ-
cus pneumonia b-1,4-galactosidase (2 mU/digest) and jack bean
b-N-acetylhexosaminidase (10 mU/digest) (all from Prozyme, San
Leandro, CA, USA).
Isolation of mucosa of mice
CT and TG mice were anesthetized and ileum was removed
and flushed with ice-cold PBS. It was cut along its length and the
mucosa was scraped off with a microscope slide. On histological
examination of the intestine it was noted that this technique
removed mainly the mucosa, leaving most of the submucosa and
all of the deeper structures intact.
RNA isolation, cDNA synthesis and qPCR on mucosal
samples
RNA of mucosa was prepared with the RNeasy Mini kit
(Qiagen Benelux B.V.,Venlo, the Netherlands). DNase digestion
was performed with the RNase-free DNase Set of Qiagen. cDNA
was prepared with the iScript cDNA synthesis kit of Bio-Rad
starting from 2 mg of total RNA. Real-time qPCR using the Light
Cycler 480 (Roche Diagnostics) was performed with a fivefold
dilution of the cDNA. Each 10 mL-assay contained 5 ml of 26Fast
SYBR Green Master Mix (Applied Biosystems, Nieuwerkerk Ad
Ijssel, The Netherlands), 2 mL primer mix for each gene (0.5 mM
each final concentration), and 3 mL of diluted cDNA. The primers
were designed with the PrimerExpress software or selected from
the Primerbank of Harvard. A geometric averaging method
(GeNorm) identified the best performing housekeeping genes
(UBC and GAPDH). Each reaction was performed in triplicate.
PCR cycling consisted of denaturation at 95uC for 5 min, 50
cycles of 95uC for 10 s and 60uC for 30 s, and detection for 1 s at
72uC. Results are given as relative expression values normalized to
the geometric mean of the housekeeping genes. Primers sequences
used were as follows: mouse bGalT1-forw: AAAATTC-
GCTGTGGCCCTC, mouse bGalT1-rev: GGCACAAT-
CATGCTGGAGAA.
In vivo TNF toxicity
Recombinant mouse TNF was produced in E. coli and purified
to homogeneity in our laboratory. It had a specific activity of
9.466107 IU/mg and endotoxin levels did not exceed 1 ng/ml of
protein. Mice were injected i.p. with a LD50 of TNF. Body
temperature and survival were monitored and blood for cytokine
analysis was collected.
Interleukin-6 measurement
To measure interleukin-6 (IL-6) in serum, we used the 7TD1
hybridoma cell line, which proliferates in response to IL-6 [71]. In
the presence of serially diluted serum or mouse IL-6 as a standard,
7000 cells per well were cultured in 96-well plates. After 72 h of
culture, the number of cells was determined by a hexosaminidase
colorimetric method. The assay has a detection limit of 1 pg/ml.
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Hematoxylin-eosin, CD45 staining, Ki67 staining, PAS
staining and MMP-7 staining
Mice were anesthetized with ketamine xylazine. The ilea or
colons were removed and flushed with cold PBS, after which they
were fixed in 4% paraformaldehyde for 24 h at 4uC. Sections of
5 mm were cut from ilea embedded in paraffin and stained with
hematoxylin (Fluka) and eosin (Merck).
For PAS staining, ileum sections were deparaffinized and
stained with the periodic acid-schiff kit (Sigma - Aldrich N.V.,
395-B).
For immunolabeling of CD45 and Ki67, ileum sections were
deparaffinized and then boiled in citrate buffer. Sections were
rinsed and incubated in 0.3% H2O2 to quench endogenous
peroxidases. Next, sections were incubated in blocking buffer
(10 mM Tris-HCl pH 7.4; 0.1 M MgCl2; 0.5% Tween20; 1%
BSA; 5% serum) for 1 h at room temperature, followed by
overnight incubation at 4uC with anti-CD45 (1:250; 550539,
Pharmingen) or anti-Ki67 primary antibody (1/30; 7249, DAKO).
After rinsing with PBS/0.1% Tween20 (PBS-T), sections were
incubated with biotinylated secondary antibody (1/300; DAKO)
for 30 min at room temperature. They were again rinsed in PBS-
T and incubated with avidin/biotin complex (Vectastain Elite
ABC kit, Vector Labs) for 20 min. After rinsing in PBS-T, sections
were incubated in AEC (Dako) for 15 min. Finally, they were
counterstained with Gills III and mounted with Aquatex.
For MMP-7 immunostaining, ileum sections were dewaxed and
boiled in 10 mM sodium citrate buffer for antigen retrieval,
incubated for 1 h in blocking buffer (10 mM Tris-HCl pH 7.4, 0.1
M MgCl2, 0.5% Tween-20, 1% BSA and 5% serum) and
incubated with MMP7 (1/100; 3801; Cell Signalling Technology)
antibody.
Fluorescent images and light microscopy images were taken by
a laser scanning confocal microscope (Leica TCS SP5) and an
Olympus light microscope respectively.
Fecal DNA extraction
Fresh feces were obtained from female cohoused CT and TG
mice of 12 weeks old and stored immediately at 280uC. DNA was
extracted from the feces using the QIAamp DNA Stool Mini Kit
(Qiagen, Venlo, The Netherlands).
Real-time qPCR analysis on fecal DNA
qPCR amplification and detection were performed using the
Roche LightCycler 480 and its SYBR Green I Master kit. Each
PCR reaction included 300 nM of forward and reverse primers,
9 ng of DNA, and SYBR Green Master Mix. Samples without
template served as negative controls. Samples were incubated at
95uC for 5 min and then amplified through 45 cycles of 95uC for
10 s, 60uC for 30 s, and 72uC for 1 s. The amount of Firmicutes
and Bacteroidetes 16S rRNA in each sample was normalized to
the total amount of 16S rRNA amplified with universal primers
(the total amount of bacteria was not different between CT and
TG mice as demonstrated by the QPCR with universal 16S
rRNA). Primers used in these experiments are the following:
Bacteroidetes: BactF GGARCATGTGGTTTAATTCGATGAT;
BactR AGCTGACGACAACCATGCAG; Firmicutes: FirmF
GGAGYATGTGGTTTAATTCGAAGCA; FirmR AGCTGAC-
GACAACCATGCAC; Total Bacteria: EubF ACTCCTACGG-
GAGGCAGCAG; EubR ATTACCGCGGCTGCTGG.
Induction of DSS-induced colitis and clinical score
Female and male CT and TG mice at the age of 9–11 weeks
were used in DSS-induced colitis experiments. Acute colitis was
induced by addition of 3% DSS (36–50 kD; MP Biomedicals) to
the drinking water for five days. Body weight, occult or gross blood
loss from the rectum, and stool consistency were determined daily.
Fecal blood was determined using Hemoccult SENSA (Beckman
Coulter). The baseline clinical score was determined on day 0. In
brief, no weight loss was scored as 0, weight loss of 1–5% of
baseline as 1, 5–10% as 2, 10–20% as 3, and .20% as 4. For
bleeding, a score of 0 was assigned for no blood, 2 for positive
hemoccult, and 4 for gross bleeding. For stool consistency, a score
of 0 was assigned for well-formed pellets, 2 for pasty and
semiformed stools, and 4 for liquid stools. For each mouse, these
scores were combined and divided by three to give an overall
clinical score ranging from 0 (healthy) to 4 (maximal colitis). To
eliminate observer bias, scoring was blinded. Postmortem, the
entire colon was removed from cecum to anus and its length was
measured as an indicator of inflammation.
Gut permeability test
FITC-labeled dextran (4 kDa, Sigma) was administered to mice
by gavage at 150 mg/kg body weight. Five hours later, blood
collected by heart puncture in EDTA-coated tubes (Sarstedt) and
plasma was prepared. Leakage of FITC-labeled dextran into the
circulation was determined by measurement of fluorescence with
lex = 488 nm and lem= 520 nm. Values were normalized to the
lowest value.
Statistics
Data were expressed as means 6 standard errors of the means
(SEM). Statistical significance between two groups was evaluated
with a two-tailed t-test with a 95% confidence interval (CI). The
log rank test was used for analysis of survival curves. All tests were
calculated with Prism software. p values,0.05 were considered
statistically significant. P values are indicated as *, **, and *** to
represent 0.01#p,0.05, 0.001#p,0.01, and p,0.001, respec-
tively.
Supporting Information
Figure S1 Relative bGalT1 gene expression and activity in CT
versus TG mice. (A) Relative bGalT1 gene expression in the liver
of TG mice (n = 4) is 2 fold higher compared to CT mice (n = 4).
(B) Relative bGalT1 gene expression in the brain of TG mice
(n = 4) is 2 fold higher compared to CT mice (n = 4). (C) bGalT1
activity in the liver of TG mice (n = 4) is upregulated 2 fold
compared to CT mice (n = 4).
(TIF)
Figure S2 Blood composition of CT versus TG mice measured
by Hemavet. Twenty ml of fresh blood from unstimulated CT and
TG mice, was obtained in EDTA-coated vials and immediately
used for measuring blood composition by Hemavet (Scientific Inc.
Oxford).
(TIF)
Figure S3 Mucus in intestine of CT versus TG mice. Staining of
the small intestine (without stimulus) with Alcian blue to visualize
the goblet cells in CT (A left) and TG (A right) mice. The
quantification was done using the program Velocity. The bar in
the left corner represents 50 mm (B) Amount of mucus present in
the intestine of CT versus TG mice. No differences were observed
between CT and TG mice. (C) Analysis of the N-glycosylation
profile of colon mucus from mice with and without hexosamin-
idase treatment. Top panel is the N-glycosylation profile of a
standard protein, RNase B. The second panel represents a
representative sample of colon mucus of a CT mouse. The third
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panel represents the N-glycosylation profile of CT mucus (the
same sample as shown in panel 2), but after hexosaminidase
treatment. The fourth panel is a representative sample of colon
mucus of a TG mouse. The fifth panel is the same sample as in the
fourth panel but after hexosaminidase treatment, demonstrating
that TG mucus has less structures ending with GlcNac compared
to CT mucus. (D) Analysis of the N-glycosylation profile of colon
mucus from mice with and without ß-galactosidase treatment.
After isolation of the N-glycans out of colon mucus, these N-
glycans are treated with ß-galactosidase in order to identify
terminal galoctose residues in the sample since ß-galactosidase
only cleaves terminal galactose. Top panel is the N-glycosylation
profile of RNase B. The second panel represents a typical sample
of colon mucus of a CT mouse. The third panel is the same sample
as the second panel but treated with ß-galactosidase. Only a few
peaks shift, which demonstrates that only a small amount of the N-
glycans in CT mucus have terminal galactose. The fourth panel is
a representative sample of colon mucus of a TG mouse. The fifth
panel is the same sample as in the fourth panel but treated with ß-
galactosidase. Here a clear shift of peaks is observed demonstrating
that the N-glycans in TG colon mucus have more terminal
galactose compared to the CT colon mucus.
(TIF)
Table S1 Primers used for the qPCR measurement of bacteria
in the gut of mice.
(TIF)
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